Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).
百慕大漢密爾頓，2024 年 5 月 7 日（GLOBE NEWSWIRE）— Kiniksa 製藥有限公司 納斯達克股票代碼：KNSA）今天宣佈，管理層將在太平洋時間2024年5月14日星期二上午10點40分（美國東部時間下午1點40分）參加美國銀行證券2024年醫療保健會議的爐邊談話。
A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa演講的網絡直播可通過該公司網站的 “投資者與媒體” 欄目觀看，網址爲 www.kiniksa.com。該活動的重播也將在活動結束後的大約48小時內在Kiniksa的網站上公佈。
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
關於 Kiniksa
Kiniksa是一家處於商業階段的生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以幫助患有虛弱性疾病、醫療需求嚴重未得到滿足的患者。Kiniksa 的免疫調節資產 ARCALYST、abiprubart和mavrilimumab基於強有力的生物學原理或經過驗證的機制，靶向一系列未得到充分治療的心血管和自身免疫疾病，並具有分化潛力。欲了解更多信息，請訪問 www.kiniksa.com。
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc.
ARCALYST 是 Regeneron Pharmicals, Inc. 的註冊商標
|
Every Second Counts! Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
|
每一秒都很重要！ Kiniksa 投資者和媒體聯繫人 瑞秋弗蘭克 (339) 970-9437 rfrank@kiniksa.com |
譯文內容由第三人軟體翻譯。